darunavir has been researched along with apixaban in 2 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (apixaban) | Trials (apixaban) | Recent Studies (post-2010) (apixaban) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 2,405 | 255 | 2,250 |
| Protein | Taxonomy | darunavir (IC50) | apixaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
2 other study(ies) available for darunavir and apixaban
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |